Moderna will present safety data on Wednesday from an early trial that provides the first glimpse of how its Covid-19 vaccine stimulates the immune system in older people.

The company will present “new interim safety and immunogenicity data from the cohorts of older adults” from its phase 1 trial, according to a statement. The results will be presented to the US Center for Disease Control and Prevention’s Advisory Committee on Immunisation Practices...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.